Scottish biotech ReNeuron announced that the first ever stroke patient to be treated with its stem cell therapy remains well a year later with no “cell-related adverse events reported” after 28 days of treatment. The success enables ReNeuron to advance to a second cohort of patients, who will receive higher doses. In all, 12 patients will be given varying doses of ReNeuron’s ReN001 stem cell treatment as part of the Scottish phase I trial. ReNeuron derives its stem cell products from non-embryonic human tissue sources.
Click here to read more.Share this: